Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
Priovant Announces Publication of Phase 2 BEACON Results for Brepocitinib in Cutaneous Sarcoidosis in JAMA Dermatology
Roivant Sciences Ltd. $ROIV Stock: CenterBook Partners LP Cuts Position
Roivant Sciences Ltd. (ROIV) Q2 2026 Earnings Call Transcript
Roivant Sciences Q2 Earnings Call Highlights
Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue Estimates
Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended September 30, 2026
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026, and Provides Business Update
Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares
Roivant Sciences (NASDAQ:ROIV) Stock: Insider Eric Venker Sells 200,000 Shares
Roivant Sciences Ltd. (ROIV) Discusses Phase 3 Results for Brepocitinib in Non-Infectious Uveitis Transcript
Roivant Sciences' Brepocitinib Delivers Positive Phase III Uveitis Results
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
Roivant Sciences Ltd. $ROIV Stock Holdings Lowered by Assenagon Asset Management S.A.
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)
Roivant’s Eric Venker sells 200,000 shares after option exercise (NASDAQ: ROIV)
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Roivant Sciences Targets LISRAYA Launch, Key Pipeline Readouts in Next 12 Months
Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
Already premium?